Parametric Portfolio Associates’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-258
| Closed | -$21K | – | 4094 |
|
|
2020
Q4 | $21K | Hold |
258
| – | – | ﹤0.01% | 3974 |
|
|
2020
Q3 | $16K | Hold |
258
| – | – | ﹤0.01% | 3911 |
|
|
2020
Q2 | $23K | Sell |
258
-313
| -55% | -$33.1K | ﹤0.01% | 3893 |
|
|
2020
Q1 | $64K | Sell |
571
-1,788
| -76% | -$352K | ﹤0.01% | 3802 |
|
|
2019
Q4 | $577K | Buy |
2,359
+894
| +61% | +$226K | ﹤0.01% | 3311 |
|
|
2019
Q3 | $504K | Buy |
1,465
+449
| +44% | +$244K | ﹤0.01% | 3339 |
|
|
2019
Q2 | $936K | Buy |
1,016
+27
| +3% | +$33.2K | ﹤0.01% | 3082 |
|
|
2019
Q1 | $1.58M | Sell |
989
-5
| -0.5% | -$9.01K | ﹤0.01% | 2785 |
|
|
2018
Q4 | $1.86M | Sell |
994
-111
| -10% | -$242K | ﹤0.01% | 2627 |
|
|
2018
Q3 | $2.6M | Buy |
1,105
+137
| +14% | +$424K | ﹤0.01% | 2530 |
|
|
2018
Q2 | $3.34M | Buy |
968
+51
| +6% | +$156K | ﹤0.01% | 2290 |
|
|
2018
Q1 | $2.6M | Buy |
917
+19
| +2% | +$56.9K | ﹤0.01% | 2429 |
|
|
2017
Q4 | $2.31M | Buy |
898
+34
| +4% | +$96.7K | ﹤0.01% | 2512 |
|
|
2017
Q3 | $2.45M | Buy |
864
+95
| +12% | +$250K | ﹤0.01% | 2447 |
|
|
2017
Q2 | $1.82M | Buy |
769
+139
| +22% | +$275K | ﹤0.01% | 2603 |
|
|
2017
Q1 | $1.59M | Buy |
630
+205
| +48% | +$590K | ﹤0.01% | 2600 |
|
|
2016
Q4 | $958K | Buy |
425
+5
| +1% | +$11.9K | ﹤0.01% | 2855 |
|
|
2016
Q3 | $1.05M | Buy |
420
+4
| +1% | +$11.9K | ﹤0.01% | 2769 |
|
|
2016
Q2 | $1.27M | Sell |
416
-21
| -5% | -$68.3K | ﹤0.01% | 2648 |
|
|
2016
Q1 | $1.39M | Buy |
437
+2
| +0.5% | +$8.3K | ﹤0.01% | 2679 |
|
|
2015
Q4 | $2.24M | Buy |
435
+67
| +18% | +$293K | ﹤0.01% | 2148 |
|
|
2015
Q3 | $1.17M | Buy |
368
+117
| +47% | +$454K | ﹤0.01% | 2222 |
|
|
2015
Q2 | $1M | Buy |
251
+14
| +6% | +$54.1K | ﹤0.01% | 2805 |
|
|
2015
Q1 | $945K | Buy |
237
+5
| +2% | +$22.9K | ﹤0.01% | 2830 |
|
|
2014
Q4 | $1.14M | Buy |
232
+19
| +9% | +$81.5K | ﹤0.01% | 2682 |
|
|
2014
Q3 | $865K | Buy |
213
+31
| +17% | +$116K | ﹤0.01% | 2815 |
|
|
2014
Q2 | $737K | Sell |
182
-6
| -3% | -$24.5K | ﹤0.01% | 2949 |
|
|
2014
Q1 | $857K | Buy |
188
+18
| +11% | +$72.8K | ﹤0.01% | 2792 |
|
|
2013
Q4 | $596K | Buy |
170
+7
| +4% | +$27.3K | ﹤0.01% | 3050 |
|
|
2013
Q3 | $668K | Buy |
163
+21
| +15% | +$90.5K | ﹤0.01% | 2896 |
|
|
2013
Q2 | $561K | Buy |
+142
| New | +$585K | ﹤0.01% | 2877 |
|
Other funds holding ACOR
Parametric Portfolio Associates's ACOR Position: Q1 2021 in Review
Parametric Portfolio Associates sold out of Acorda Therapeutics (ACOR) in Q1 2021, closing a stake of 258 shares — an estimated $21K sold.
Parametric Portfolio Associates first reported a position in ACOR in Q2 2013 and held it in 31 quarters. The position peaked at $3.34M in Q2 2018. 32 funds tracked by Wall St. Rank hold ACOR as of Q1 2021.
- Parametric Portfolio Associates reported no remaining Acorda Therapeutics position as of Q1 2021 after selling out during the quarter.
- Parametric Portfolio Associates sold 258 Acorda Therapeutics shares in Q1 2021, an estimated $21K.
- Parametric Portfolio Associates first reported a position in Acorda Therapeutics in Q2 2013 and held it in 31 quarters.
- Parametric Portfolio Associates's Acorda Therapeutics position peaked at $3.34M in Q2 2018.
- 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2021.
Based on Parametric Portfolio Associates's 13F filing for Q1 2021, filed 17 May 2021.